LMAT 8-K
Lemaitre Vascular Inc (LMAT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 28, 2020
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-33092
|
Delaware |
|
04-2825458 |
|
(State or other jurisdiction of |
|
(IRS Employer |
|
incorporation) |
|
Identification No.) |
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
781-221-2266
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class |
Trading symbol |
Name of exchange on which registered |
|
Common stock, $0.01 par value per share |
LMAT |
The Nasdaq Global Market |
Item 2.02. Results of Operations and Financial Condition.
On April 30, 2020, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Report.
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Upon recommendation from the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of the Company, on April 28, 2020, the Board appointed Bridget A. Ross as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case effective as of such date, to fill a vacancy on the Board due to the death of Michael H. Thomas. Ms. Ross will serve as a Class II director and will hold office until the Company’s 2020 annual stockholders meeting, subject to her earlier resignation, removal or death.
There are no arrangements or understandings between Ms. Ross and any other persons pursuant to which she was selected as a director. Ms. Ross has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Ms. Ross will be compensated according to the Company's Non-Employee Director Compensation Policy and will also be entitled to indemnification pursuant to the standard indemnification agreement between the Company and its officers and directors.
Under the Non-Employee Director Compensation Policy, non-employee directors of the Company receive an annual retainer for Board membership of $10,000 and an annual retainer for each committee membership of $1,000, except that members of the Audit Committee receive an annual retainer for committee membership of $2,500. The chairmen of the Company's committees receive an annual retainer of $5,000, except that the chairman of the Audit Committee receives an annual retainer of $15,000. Annual retainer payments are pro-rated based upon days of service in the event a non-employee director joins or leaves the Board during any calendar year. Non-employee directors also receive a fee of $2,500 for each regularly scheduled quarterly Board meeting attended in person, $1,000 for each regularly scheduled quarterly Board meeting attended by telephone or videoconferencing, $500 for each special Board meeting attended either in person or by telephone or videoconferencing, and $500 for each committee meeting attended either in person or by telephone or teleconference. Aggregate cash compensation paid to any non-employee director for any year may not exceed $40,000 without the approval of the Board.
For the remainder of 2020, non-employee directors of the Board, including Ms. Ross, will not receive any cash compensation in respect of their service on the Board.
As a non-employee director, Ms. Ross will also be eligible to receive (i) an option to purchase 20,000 shares of the Company's common stock in connection with her initial appointment to the Board and (ii) an option to purchase 7,500 shares of the Company's common stock at the first Board meeting following each annual meeting of the Company's stockholders, provided that she has served as a director for at least six months at such time.
Ms. Ross will also be reimbursed for out-of-pocket expenses incurred on the Company's behalf and be eligible to participate in the Third Amended and Restated 2006 Stock Option and Incentive Plan on an ad hoc basis from time to time at the discretion of the Board.
Item 9.01. Financial Statements and Exhibits.
The following exhibits are furnished or filed as part of this Report, as applicable:
|
|
(d) |
Exhibits. |
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press release issued by LeMaitre Vascular, Inc. on April 30, 2020. |
Exhibit Index
|
|
||
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press release issued by LeMaitre Vascular, Inc. on April 30, 2020. |
Signature(s)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
LeMaitre Vascular, Inc. |
||
|
|
||
|
|
||
|
Date: April 30, 2020 |
By: |
Joseph P. Pellegrino, Jr. /s/ JOSEPH P. PELLEGRINO, JR. |
|
|
|
Joseph P. Pellegrino, Jr. Chief Financial Officer |
Exhibit 99.1
|
LeMaitre Vascular Announces Q1 2020 Financial Results |
BURLINGTON, MA, April 30, 2020 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2020 results and announced a $0.095/share quarterly dividend.
Q1 2020 Results
|
● |
Record sales of $30.6mm, +7% (-1% organic) vs. Q1 2019 |
|
● |
Operating income of $4.4mm, -2% |
|
● |
Net income of $3.2mm, -10% |
|
● |
Earnings of $0.16 per diluted share, -11% |
|
● |
EBITDA of $5.7mm, +1% |
|
● |
March 31, 2020 cash & equivalents of $30.6mm |
The Company posted record sales in the Americas (+12%) and Europe/Middle East/Africa (+3%), offset by Asia/Pac (-11%). Sales growth was led by biologic patches, allografts and valvulotomes, and was aided by the two 2019 acquisitions.
Gross margin decreased to 67.0% in Q1 2020 (vs. 68.3% in Q1 2019) primarily due to manufacturing inefficiencies and increased allograft sales.
Operating expenses in Q1 2020 were up 7% to $16.1mm (vs. $15.0mm) driven by MDD/MDR regulatory expenses, production transfers and acquisition amortization.
Chairman and CEO George LeMaitre said, “COVID-19 began to affect our sales in mid-March, and we expect our results to be impacted for the balance of 2020. As a result, we’ve reduced headcount and temporarily cut base salaries. My base salary was cut 90% while our lowest earners’ hourly wages were not impacted. These actions were necessary to protect our profitability and cash position. We implemented social-distancing in our four factories and they’re generally operating at near-normal levels.”
Business Outlook
On April 13, 2020, the Company withdrew its guidance for the full year 2020. Due to the unpredictable magnitude and duration of the COVID-19 pandemic and the timing of possible global economic recovery, the Company is unable to estimate the overall impacts on its financial results for the remainder of 2020.
Quarterly Dividend
On April 28, 2020, the Company's Board of Directors approved a quarterly dividend of $0.095/share of common stock. The dividend will be paid on June 4, 2020 to shareholders of record on May 20, 2020.
Share Repurchase Program
On February 13, 2020, the Company's Board of Directors authorized the repurchase of up to $10.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 14, 2021, unless extended by the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. ET today to review the Company's Q1 2020 financial results. The conference call will be broadcast live over the Internet. Individuals who are interested in listening to the webcast should log on to the Company's website at www.lemaitre.com/investor. The conference call may also be accessed by dialing 844-239-5284 (+1 512-961-6497 for international callers), using passcode 3349306. For individuals unable to join the live conference call, a replay will be available on the Company's website.
A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
LeMaitre and the LeMaitre Vascular logo are registered trademarks of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
For more information about the Company, please visit http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to better understand the Company's short-term and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.
In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events as well as EBITDA or earnings before interest, taxes, depreciation and amortization. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and EBITDA to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that evaluating EBITDA provides an approximation of the cash generating ability of its operations.
Forward-Looking Statements
The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; compliance with foreign regulatory requirements to market our products outside the United States; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: J.J. Pellegrino, CFO, LeMaitre Vascular
781-425-1691
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) |
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
(amounts in thousands) |
|
March 31, 2020 |
December 31, 2019 |
|||||||
|
(unaudited) |
||||||||
|
Assets |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | 10,944 | $ | 11,786 | ||||
|
Short-term marketable securities |
19,687 | 20,895 | ||||||
|
Accounts receivable, net |
16,630 | 16,572 | ||||||
|
Inventory and other deferred costs |
40,580 | 39,527 | ||||||
|
Prepaid expenses and other current assets |
1,881 | 3,312 | ||||||
|
Total current assets |
89,722 | 92,092 | ||||||
|
Property and equipment, net |
14,791 | 14,854 | ||||||
|
Right-of-use leased assets |
14,883 | 15,208 | ||||||
|
Goodwill |
39,773 | 39,951 | ||||||
|
Other intangibles, net |
24,059 | 24,893 | ||||||
|
Deferred tax assets |
1,069 | 1,084 | ||||||
|
Other assets |
260 | 259 | ||||||
|
Total assets |
$ | 184,557 | $ | 188,341 | ||||
|
Liabilities and stockholders' equity |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | 1,381 | $ | 2,604 | ||||
|
Accrued expenses |
11,015 | 14,014 | ||||||
|
Acquisition-related obligations |
2,495 | 2,476 | ||||||
|
Lease liabilities - short-term |
1,703 | 1,757 | ||||||
|
Total current liabilities |
16,594 | 20,851 | ||||||
|
Lease liabilities - long-term |
13,715 | 13,955 | ||||||
|
Deferred tax liabilities |
1,176 | 1,179 | ||||||
|
Other long-term liabilities |
4,237 | 4,215 | ||||||
|
Total liabilities |
35,722 | 40,200 | ||||||
|
Stockholders' equity |
||||||||
|
Common stock |
217 | 217 | ||||||
|
Additional paid-in capital |
106,946 | 105,934 | ||||||
|
Retained earnings |
58,286 | 57,029 | ||||||
|
Accumulated other comprehensive loss |
(5,525 | ) | (4,007 | ) | ||||
|
Treasury stock |
(11,089 | ) | (11,032 | ) | ||||
|
Total stockholders' equity |
148,835 | 148,141 | ||||||
|
Total liabilities and stockholders' equity |
$ | 184,557 | $ | 188,341 | ||||
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) |
|
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS |
|
(amounts in thousands, except per share amounts) |
|
(unaudited) |
|
For the three months ended |
||||||||
|
March 31, 2020 |
March 31, 2019 |
|||||||
|
Net sales |
$ | 30,551 | $ | 28,479 | ||||
|
Cost of sales |
10,068 | 9,015 | ||||||
|
Gross profit |
20,483 | 19,464 | ||||||
|
Operating expenses: |
||||||||
|
Sales and marketing |
7,945 | 7,845 | ||||||
|
General and administrative |
5,191 | 4,944 | ||||||
|
Research and development |
2,994 | 2,240 | ||||||
|
Total operating expenses |
16,130 | 15,029 | ||||||
|
Income from operations |
4,353 | 4,435 | ||||||
|
Other income: |
||||||||
|
Other income (loss), net |
(73 | ) | 78 | |||||
|
Income before income taxes |
4,280 | 4,513 | ||||||
|
Provision for income taxes |
1,106 | 1,000 | ||||||
|
Net income |
$ | 3,174 | $ | 3,513 | ||||
|
Earnings per share of common stock |
||||||||
|
Basic |
$ | 0.16 | $ | 0.18 | ||||
|
Diluted |
$ | 0.16 | $ | 0.17 | ||||
|
Weighted - average shares outstanding: |
||||||||
|
Basic |
20,168 | 19,640 | ||||||
|
Diluted |
20,438 | 20,205 | ||||||
|
Cash dividends declared per common share |
$ | 0.095 | $ | 0.085 | ||||
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) |
|
SELECTED NET SALES INFORMATION |
|
(amounts in thousands) |
|
(unaudited) |
|
For the three months ended |
||||||||||||||||
|
March 31, 2020 |
March 31, 2019 |
|||||||||||||||
| $ |
% |
$ |
% |
|||||||||||||
|
Net Sales by Geography |
||||||||||||||||
|
Americas |
$ | 18,336 | 60 | % | $ | 16,375 | 58 | % | ||||||||
|
Europe/Middle East/Africa |
10,350 | 34 | % | 10,013 | 35 | % | ||||||||||
|
Asia/Pacific Rim |
1,865 | 6 | % | 2,091 | 7 | % | ||||||||||
|
Total Net Sales |
$ | 30,551 | 100 | % | $ | 28,479 | 100 | % | ||||||||
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) |
|
NON-GAAP FINANCIAL MEASURES |
|
(amounts in thousands) |
|
(unaudited) |
|
Reconciliation between GAAP and Non-GAAP sales growth: |
||||||||||||
|
For the three months ended March 31, 2020 |
||||||||||||
|
Net sales as reported |
$ | 30,551 | ||||||||||
|
Impact of currency exchange rate fluctuations |
285 | |||||||||||
|
Net impact of acquisitions excluding currency |
(2,594 | ) | ||||||||||
|
Adjusted net sales |
$ | 28,242 | ||||||||||
|
For the three months ended March 31, 2019 |
||||||||||||
|
Net sales as reported |
$ | 28,479 | ||||||||||
|
Adjusted net sales decrease for the three months ended March 31, 2020 |
$ | (237 | ) | -1 | % | |||||||
|
For the three months ended |
||||||||||||
|
March 31, 2020 |
March 31, 2019 |
|||||||||||
|
Reconciliation between GAAP and Non-GAAP EBITDA |
||||||||||||
|
Net income as reported |
$ | 3,174 | $ | 3,513 | ||||||||
|
Interest (income) expense, net |
(105 | ) | (157 | ) | ||||||||
|
Amortization and depreciation expense |
1,538 | 1,284 | ||||||||||
|
Provision for income taxes |
1,106 | 1,000 | ||||||||||
|
EBITDA |
$ | 5,713 | $ | 5,640 | ||||||||
|
EBITDA percentage increase |
1 | % | ||||||||||